100
Participants
Start Date
August 1, 2024
Primary Completion Date
February 1, 2025
Study Completion Date
August 1, 2025
sofosbuvir/velpatasvir
Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.
Eastern Idaho Public Health
OTHER_GOV